Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for Episodic Migraine
- Study Title
- Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
- Teva Identifier
- TV48125-CNS-30050 | 2015-004598-34
- ClinicalTrials.gov Identifier
- NCT02629861
- Study Status
- Completed
- Trial Condition(s)
- Migraine
- Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- March 23, 2016 - April 10, 2017
- Phase
- Phase 3
